Palatin Technologies, Inc. March 31, 2011 Quarter Results; Teleconference and Webcast to be Held on May 16, 2011

CRANBURY, N.J., May 12, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended March 31, 2011 financial results and its programs, focusing on the upcoming start of its Phase 2 clinical trial with bremelanotide for women with female sexual dysfunction.  

Schedule for the Financial Results Press Release, Conference Call / Webcast



Q3 Fiscal Year 2011 Conference Call-Live

5/16/2011 at 11:00 a.m. ET

Domestic Dial-In Number

1-866-316-1363

International Dial-In Number

1-913-312-0861

Pass code

2950108



Q3 Fiscal Year 2011 Conference Call-Replay

5/16-5/23/2011

Domestic Dial-In Number

1-888-203-1112

International Dial-In Number

1-719-457-0820

Pass code

2950108



Webcast Live and Replay Access

http://www.palatin.com



The webcast and replay can be accessed by logging on to the “Investor/Media Center-Webcasts” section of Palatin’s website at http://www.palatin.com



About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule agonists with a focus on melanocortin and natriuretic peptide receptor systems. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

SOURCE Palatin Technologies, Inc.

Suggested Articles

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.

The Merck-backed round positions Themis to take its chikungunya vaccine through phase 3 and start testing a cancer drug in humans.